( Clear Anti-Inflammatory Activity Demons...)ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference,Health

MOUNTAIN VIEW, Calif., May 23, 2007 /PRNewswire/ -- ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, presented data today from the company's Phase 2 clinical trial of Traficet-EN (CCX282-B), an orally-active anti-inflammatory agent that targets the chemokine receptor CCR9. Clinical results demonstrate that Traficet-EN is well tolerated and shows clinical activity in the treatment of patients with active Crohn's disease. These data (Abstract #1031) were presented in an oral session, "Advances in Crohn's Disease," at the Digestive Disease Week (DDW) 2007 Conference in Washington, D.C. by Satish Keshav, M.D., Ph.D., Gastroenterologist at the John Radcliffe Hospital, Oxford, and a clinical investigator for the study.

"Traficet-EN demonstrated promising evidence of efficacy in the treatment of Crohn's disease patients, particularly among patients with elevated CDAI and CRP measurements at baseline. These results, achieved after only four weeks of treatment, justify broader study of Traficet-EN," said Dr. Keshav. "Traficet-EN's potential to control Crohn's disease with a safe and effective oral capsule represents a paradigm shift in the treatment of this condition and a truly meaningful improvement in patient care."

Patients enrolled in the Phase 2 clinical trial were randomized to receive a once-daily 250 mg capsule of Traficet-EN or placebo for 28 days. Both Crohn's Disease Activity Index (CDAI) scores and C-reactive protein (CRP) levels were measured at baseline and on study days 8, 15 and 29. Among a defined subgroup of 39 patients identified as having more active disease, with CDAI scores of greater than or equal to 250 and CRP of greater than 7.5 mg/L at baseline, Traficet-EN demonstr
'"/>